AMLXAmylyx Pharmaceuticals, Inc.

HealthcareUSD
$37.06

The financials

Amylyx Pharmaceuticals, Inc. by the numbers

For the full year FY2025, revenue was $0 (−100% year on year) and net income −$145M.

Amylyx Pharmaceuticals, Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenuen/a$0n/a
Gross profitn/a$0n/a
Operating income−$44M−$38Mn/a
Net income−$41M−$36Mn/a
Diluted EPS−$0.37−$0.42n/a

Drug Manufacturers - Specialty & Generic

Ranks #3 of 28 by Smart Score

Compare peers
BHC+5.8%
Bausch Health Companies Inc.
ANIP+0.68%
ANI Pharmaceuticals, Inc.
HCM+0.19%
HUTCHMED (China) Limited
PBH-0.30%
Prestige Consumer Healthcare Inc.
HROW-2.8%
Harrow, Inc.
BCRX-1.0%
BioCryst Pharmaceuticals, Inc.